Literature DB >> 216522

The absence of 24,25-dihydroxycholecalciferol in anephric patients.

C M Taylor, E B Mawer, J E Wallace, J St John, M Cochran, R G Russell, J A Kanis.   

Abstract

1. In subjects with normal renal function there was a strong positive correlation between serum concentrations of 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol, as measured by competitive protein-binding assay. 2. The 24,25-dihydroxycholecalciferol concentration was about 7% of the prevailing 25-hydroxycholecalciferol concentration. 3. In contrast, sera from anephric patients contained very low or undetectable amounts of 24,25-dihydroxycholecalciferol even after the serum 25-hydroxycholecalciferol concentrations in these patients had been elevated by oral administration of 25-hydroxycholecalciferol. 4. In a further group of anephric patients, all having normal serum 25-hydroxycholecalciferol concentrations, no radioactively labelled 24,25-dihydroxycholecalciferol was formed from an injected pulse dose of [3H,14C]cholecalciferol. 5. These results indicate that in man the kidney is the major site of 24-hydroxylation of 25-hydroxycholecalciferol.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 216522     DOI: 10.1042/cs0550541

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  9 in total

Review 1.  Therapeutic applications of vitamin D analogues.

Authors:  J Reeve
Journal:  Br Med J       Date:  1979-10-13

2.  Sequential changes in mineral metabolism and serum vitamin D metabolite concentrations produced by phenobarbital administration in the rat.

Authors:  T J Hahn; L R Halstead
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

3.  Extrarenal metabolism of 25-hydroxycholecalciferol in the rat: regulation by 1,25-dihydroxycholecalciferol.

Authors:  R T Turner; R C Avioli; N H Bell
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

4.  Serum vitamin D metabolites in cadmium-exposed persons with renal damage.

Authors:  K Nogawa; I Tsuritani; T Kido; R Honda; M Ishizaki; Y Yamada
Journal:  Int Arch Occup Environ Health       Date:  1990       Impact factor: 3.015

5.  Vitamin D deficiency, osteomalacia, and primary biliary cirrhosis. Response to orally administered vitamin D3.

Authors:  M Davies; E B Mawer; H J Klass; G A Lumb; J L Berry; T W Warnes
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

6.  Seasonal fluctuations in serum concentrations of vitamin D metabolites in normal subjects.

Authors:  J R Juttmann; T J Visser; C Buurman; E de Kam; J C Birkenhäger
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

7.  Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3.

Authors:  J E Griffin; J E Zerwekh
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  Localization of 25-hydroxyvitamin D3 1 alpha-hydroxylase and 24-hydroxylase along the rat nephron.

Authors:  H Kawashima; S Torikai; K Kurokawa
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

9.  Evidence for extrarenal production of 1 alpha ,25-dihydroxyvitamin D in man.

Authors:  P W Lambert; P H Stern; R C Avioli; N C Brackett; R T Turner; A Greene; I Y Fu; N H Bell
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.